Abnormalities in brain structure and biochemistry associated with mdx mice measured by in vivo MRI and high resolution localized 1H MRS

Neuromuscular Disorders

Volumn 25, Issue 10, 2015, Pages 764-772

  Xu, Su ^a   Shi, Da ^a   Pratt, Stephen J P ^a   Zhu, Wenjun ^a   Marshall, Andrew ^a   Lovering, Richard M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Diffusion tensor imaging; DMD; Dystrophy; Magnetic resonance imaging; Magnetic resonance spectroscopy; Skeletal muscle

Indexed keywords

4 AMINOBUTYRIC ACID; GLUTATHIONE; PHOSPHORYLCHOLINE; TAURINE;

ANIMAL TISSUE; ARTICLE; BRAIN VENTRICLE DILATATION; CONTROLLED STUDY; DIFFUSION TENSOR IMAGING; DUCHENNE MUSCULAR DYSTROPHY; FRACTIONAL ANISOTROPY; HIPPOCAMPUS; LATERAL BRAIN VENTRICLE; MALE; MOUSE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE; ANIMAL; BRAIN; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; BRAIN; DIFFUSION TENSOR IMAGING; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED MDX; MUSCULAR DYSTROPHY, DUCHENNE; PROTON MAGNETIC RESONANCE SPECTROSCOPY;

EID: 84941732050     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2015.07.003     Document Type: Article

References (86)

1. McDonald C.M., Abresch R.T., Carter G.T., et al. Profiles of neuromuscular diseases. Duchenne muscular dystrophy. Am J Phys Med Rehabil 1995, 74:S70-92.
2. Brooke M.H., Fenichel G.M., Griggs R.C., et al. Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy. Neurology 1989, 39:475-481.
3. Lovering R.M., Porter N.C., Bloch R.J. The muscular dystrophies: from genes to therapies. Phys Ther 2005, 85:1372-1388.
4. Tinsley J.M., Blake D.J., Zuellig R.A., Davies K.E. Increasing complexity of the dystrophin-associated protein complex. Proc Natl Acad Sci U S A 1994, 91:8307-8313.
5. Blake D.J., Tinsley J.M., Davies K.E. Utrophin: a structural and functional comparison to dystrophin. Brain Pathol 1996, 6:37-47.
6. Duchenne G. I'Electrisation Localisee at de son Application a la Pathologie at a la Therapeutique 1861, Bailliere et Fils, Paris.
7. Anderson J.L., Head S.I., Rae C., Morley J.W. Brain function in Duchenne muscular dystrophy. Brain 2002, 125:4-13.
8. Nardes F., Araujo A.P., Ribeiro M.G. Mental retardation in Duchenne muscular dystrophy. J Pediatr (Rio J) 2012, 88:6-16.
9. Cotton S.M., Voudouris N.J., Greenwood K.M. Association between intellectual functioning and age in children and young adults with Duchenne muscular dystrophy: further results from a meta-analysis. Dev Med Child Neurol 2005, 47:257-265.
10. Hinton V.J., Fee R.J., Goldstein E.M., De Vivo D.C. Verbal and memory skills in males with Duchenne muscular dystrophy. Dev Med Child Neurol 2007, 49:123-128.
11. Wingeier K., Giger E., Strozzi S., et al. Neuropsychological impairments and the impact of dystrophin mutations on general cognitive functioning of patients with Duchenne muscular dystrophy. J Clin Neurosci 2011, 18:90-95.
12. Cotton S., Voudouris N.J., Greenwood K.M. Intelligence and Duchenne muscular dystrophy: full-scale, verbal, and performance intelligence quotients. Dev Med Child Neurol 2001, 43:497-501.
13. Wicksell R.K., Kihlgren M., Melin L., Eeg-Olofsson O. Specific cognitive deficits are common in children with Duchenne muscular dystrophy. Dev Med Child Neurol 2004, 46:154-159.
14. Marini A., Lorusso M.L., D'Angelo M.G., et al. Evaluation of narrative abilities in patients suffering from duchenne muscular dystrophy. Brain Lang 2007, 102:1-12.
15. Muntoni F., Mateddu A., Serra G. Passive avoidance behaviour deficit in the mdx mouse. Neuromuscul Disord 1991, 1:121-123.
16. Perronnet C., Chagneau C., Le B.P., et al. Upregulation of brain utrophin does not rescue behavioral alterations in dystrophin-deficient mice. Hum Mol Genet 2012, 21:2263-2276.
17. Vaillend C., Rendon A., Misslin R., Ungerer A. Influence of dystrophin-gene mutation on mdx mouse behavior. I. Retention deficits at long delays in spontaneous alternation and bar-pressing tasks. Behav Genet 1995, 25:569-579.
18. Yoshioka M., Okuno T., Honda Y., Nakano Y. Central nervous system involvement in progressive muscular dystrophy. Arch Dis Child 1980, 55:589-594.
19. Chen D.H., Takeshima Y., Ishikawa Y., Ishikawa Y., Minami R., Matsuo M. A novel deletion of the dystrophin S-promoter region cosegregating with mental retardation. Neurology 1999, 52:638-640.
20. Rae C., Scott R.B., Thompson C.H., et al. Brain biochemistry in Duchenne muscular dystrophy: a 1H magnetic resonance and neuropsychological study. J Neurol Sci 1998, 160:148-157.
21. Kreis R., Wingeier K., Vermathen P., et al. Brain metabolite composition in relation to cognitive function and dystrophin mutations in boys with Duchenne muscular dystrophy. NMR Biomed 2011, 24:253-262.
22. Tracey I., Dunn J.F., Parkes H.G., Radda G.K. An in vivo and in vitro H-magnetic resonance spectroscopy study of mdx mouse brain: abnormal development or neural necrosis?. J Neurol Sci 1996, 141:13-18.
23. Cyrulnik S.E., Hinton V.J. Duchenne muscular dystrophy: a cerebellar disorder?. Neurosci Biobehav Rev 2008, 32:486-496.
24. Tracey I., Dunn J.F., Radda G.K. Brain metabolism is abnormal in the mdx model of Duchenne muscular dystrophy. Brain 1996, 119(Pt 3):1039-1044.
25. Uchino M., Yoshioka K., Miike T., et al. Dystrophin and dystrophin-related protein in the brains of normal and mdx mice. Muscle Nerve 1994, 17:533-538.
26. Koenig M., Monaco A.P., Kunkel L.M. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell 1988, 53:219-228.
27. Lansman J.B., Franco A. What does dystrophin do in normal muscle?. J Muscle Res Cell Motil 1991, 12:409-411.
28. 2+ signaling. Am J Physiol Cell Physiol 2009, 297:C571-80.
29. Gee S.H., Madhavan R., Levinson S.R., Caldwell J.H., Sealock R., Froehner S.C. Interaction of muscle and brain sodium channels with multiple members of the syntrophin family of dystrophin-associated proteins. J Neurosci 1998, 18:128-137.
30. Kong J., Anderson J.E. Dystrophin is required for organizing large acetylcholine receptor aggregates. Brain Res 1999, 839:298-304.
31. Pratt S.J., Shah S.B., Ward C.W., Inacio M.P., Stains J.P., Lovering R.M. Effects of in vivo injury on the neuromuscular junction in healthy and dystrophic muscles. J Physiol 2013, 591:559-570.
32. Khairallah R.J., Shi G., Sbrana F., et al. Microtubules underlie dysfunction in duchenne muscular dystrophy. Sci Signal 2012, 5:ra56.
33. Whitehead N.P., Yeung E.W., Allen D.G. Muscle damage in mdx (dystrophic) mice: role of calcium and reactive oxygen species. Clin Exp Pharmacol Physiol 2006, 33:657-662.
34. Franklin K.B.J., Paxinos G. The mouse brain in stereotaxic coordinates 2007, Elsevier and Academic Press, San Diego. 3rd ed.
35. Xu S., Ji Y., Chen X., Yang Y., Gullapalli R.P., Masri R. In vivo high-resolution localized (1) H MR spectroscopy in the awake rat brain at 7 T. Magn Reson Med 2013, 69:937-943.
36. Provencher S.W. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed 2001, 14:260-264.
37. Zhuo J., Xu S., Proctor J.L., et al. Diffusion kurtosis as an in vivo imaging marker for reactive astrogliosis in traumatic brain injury. Neuroimage 2012, 59:467-477.
38. Golmohammadi M.G., Blackmore D.G., Large B., et al. Comparative analysis of the frequency and distribution of stem and progenitor cells in the adult mouse brain. Stem Cells 2008, 26:979-987.
39. Petrof B.J. Molecular pathophysiology of myofiber injury in deficiencies of the dystrophin-glycoprotein complex. Am J Phys Med Rehabil 2002, 81:S162-74.
40. Rando T.A. The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle Nerve 2001, 24:1575-1594.
41. Muntoni F., Torelli S., Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2003, 2:731-740.
42. Garcia-Tovar C.G., Perez A., Luna J., et al. Biochemical and histochemical analysis of 71 kDa dystrophin isoform (Dp71f) in rat brain. Acta Histochem 2001, 103:209-224.
43. Daoud F., Angeard N., Demerre B., et al. Analysis of Dp71 contribution in the severity of mental retardation through comparison of Duchenne and Becker patients differing by mutation consequences on Dp71 expression. Hum Mol Genet 2009, 18:3779-3794.
44. Moizard M.P., Toutain A., Fournier D., et al. Severe cognitive impairment in DMD: obvious clinical indication for Dp71 isoform point mutation screening. Eur J Hum Genet 2000, 8:552-556.
45. Taylor P.J., Betts G.A., Maroulis S., et al. Dystrophin gene mutation location and the risk of cognitive impairment in Duchenne muscular dystrophy. PLoS ONE 2010, 5:e8803.
46. Lenk U., Hanke R., Thiele H., Speer A. Point mutations at the carboxy terminus of the human dystrophin gene: implications for an association with mental retardation in DMD patients. Hum Mol Genet 1993, 2:1877-1881.
47. Culligan K., Ohlendieck K. Diversity of the brain dystrophin-glycoprotein complex. J Biomed Biotechnol 2002, 2:31-36.
48. Lidov H.G., Byers T.J., Watkins S.C., Kunkel L.M. Localization of dystrophin to postsynaptic regions of central nervous system cortical neurons. Nature 1990, 348:725-728.
49. Kim T.W., Wu K., Xu J.L., Black I.B. Detection of dystrophin in the postsynaptic density of rat brain and deficiency in a mouse model of Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 1992, 89:11642-11644.
50. Nico B., Frigeri A., Nicchia G.P., et al. Severe alterations of endothelial and glial cells in the blood-brain barrier of dystrophic mdx mice. Glia 2003, 42:235-251.
51. Goodnough C.L., Gao Y., Li X., et al. Lack of dystrophin results in abnormal cerebral diffusion and perfusion in vivo. Neuroimage 2014, 102(Pt 2):809-816.
52. Warskulat U., Flogel U., Jacoby C., et al. Taurine transporter knockout depletes muscle taurine levels and results in severe skeletal muscle impairment but leaves cardiac function uncompromised. FASEB J 2004, 18:577-579.
53. Huxtable R.J. Physiological actions of taurine. Physiol Rev 1992, 72:101-163.
54. Conte C.D., Tricarico D., Pierno S., et al. Taurine and skeletal muscle disorders. Neurochem Res 2004, 29:135-142.
55. Hollingworth S., Zeiger U., Baylor S.M. Comparison of the myoplasmic calcium transient elicited by an action potential in intact fibres of mdx and normal mice. J Physiol 2008, 586:5063-5075.
56. Woods C.E., Novo D., DiFranco M., Vergara J.L. The action potential-evoked sarcoplasmic reticulum calcium release is impaired in mdx mouse muscle fibres. J Physiol 2004, 557:59-75.
57. 2+]i and muscle damage in the mdx mouse. J Physiol 2005, 562:367-380.
58. Hernandez-Ochoa E.O., Pratt S.J., Garcia-Pelagio K.P., Schneider M.F., Lovering R.M. Disruption of action potential and calcium signaling properties in malformed myofibers from dystrophin-deficient mice. Physiol Rep 2015, 3(4):e12366. pii. 10.14814/phy2.12366.
59. Woods C.E., Novo D., DiFranco M., Capote J., Vergara J.L. Propagation in the transverse tubular system and voltage dependence of calcium release in normal and mdx muscle fibres. J Physiol 2005, 568:867-880.
60. 2+ channel function is linked to dystrophin expression in mammalian muscle. PLoS ONE 2008, 3:e1762.
61. 2+]i and muscle damage in the mdx mouse. J Physiol 2005, 562:367-380.
62. Kar N.C., Pearson C.M. Catalase, superoxide dismutase, glutathione reductase and thiobarbituric acid-reactive products in normal and dystrophic human muscle. Clin Chim Acta 1979, 94:277-280.
63. Mizuno Y. Changes in superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase activities and thiobarbituric acid-reactive products levels in early stages of development in dystrophic chickens. Exp Neurol 1984, 84:58-73.
64. Murphy M.E., Kehrer J.P. Activities of antioxidant enzymes in muscle, liver and lung of chickens with inherited muscular dystrophy. Biochem Biophys Res Commun 1986, 134:550-556.
65. Rae C., Griffin J.L., Blair D.H., et al. Abnormalities in brain biochemistry associated with lack of dystrophin: studies of the mdx mouse. Neuromuscul Disord 2002, 12:121-129.
66. Kanfer J.N., McCartney D.G. Reduced phosphorylcholine hydrolysis by homogenates of temporal regions of Alzheimer's brain. Biochem Biophys Res Commun 1986, 139:315-319.
67. Pettegrew J.W., Moossy J., Withers G., McKeag D., Panchalingam K. 31P nuclear magnetic resonance study of the brain in Alzheimer's disease. J Neuropathol Exp Neurol 1988, 47:235-248.
68. Sok D.E. Oxidative inactivation of brain alkaline phosphatase responsible for hydrolysis of phosphocholine. J Neurochem 1999, 72:355-362.
69. Reggiani C. Between channels and tears: aim at ROS to save the membrane of dystrophic fibres. J Physiol 2008, 586:1779.
70. Knuesel I., Mastrocola M., Zuellig R.A., Bornhauser B., Schaub M.C., Fritschy J.M. Short communication: altered synaptic clustering of GABAA receptors in mice lacking dystrophin (mdx mice). Eur J Neurosci 1999, 11:4457-4462.
71. Goyenvalle A., Griffith G., Babbs A., et al. Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. Nat Med 2015, 21:270-275.
72. Chamberlain J.S., Metzger J., Reyes M., Townsend D., Faulkner J.A. Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J 2007, 21:2195-2204.
73. Glesby M.J., Rosenmann E., Nylen E.G., Wrogemann K. Serum CK, calcium, magnesium, and oxidative phosphorylation in mdx mouse muscular dystrophy. Muscle Nerve 1988, 11:852-856.
74. Muntoni F., Mateddu A., Marchei F., Clerk A., Serra G. Muscular weakness in the mdx mouse. J Neurol Sci 1993, 120:71-77.
75. De la P.S., Morin S., Koenig J. Characteristics of skeletal muscle in mdx mutant mice. Int Rev Cytol 1999, 191:99-148.
76. Dangain J., Vrbova G. Muscle development in mdx mutant mice. Muscle Nerve 1984, 7:700-704.
77. Dubowitz V., Crome L. The central nervous system in Duchenne muscular dystrophy. Brain 1969, 92:805-808.
78. Bresolin N., Castelli E., Comi G.P., et al. Cognitive impairment in Duchenne muscular dystrophy. Neuromuscul Disord 1994, 4:359-369.
79. Schmidt B., Watters G.V., Rosenblatt B., Silver K. Increased head circumference in patients with Duchenne muscular dystrophy. Ann Neurol 1985, 17:620-621.
80. Appleton R.E., Bushby K., Gardner-Medwin D., Welch J., Kelly P.J. Head circumference and intellectual performance of patients with Duchenne muscular dystrophy. Dev Med Child Neurol 1991, 33:884-890.
81. Rosman N.P., Kakulas B.A. Mental deficiency associated with muscular dystrophy. A neuropathological study. Brain 1966, 89:769-788.
82. Rosman N.P. The cerebral defect and myopathy in Duchenne muscular dystrophy. A comparative clinicopathological study. Neurology 1970, 20:329-335.
83. Septien L., Gras P., Borsotti J.P., Giroud M., Nivelon J.L., Dumas R. Mental development in Duchenne muscular dystrophy. Correlation of data of the brain scanner]. Pediatrie 1991, 46:817-819.
84. al-Qudah A.A., Kobayashi J., Chuang S., Dennis M., Ray P. Etiology of intellectual impairment in Duchenne muscular dystrophy. Pediatr Neurol 1990, 6:57-59.
85. Ortiz J.G., Negron A.E., Garcia M.T., Rosado J.E., Maldonaldo C.S. The C57BL/10Bg sps/sps mouse: a mutant with absence-like seizures; neurochemical and behavioral correlates. Neurosci Lett 1990, 114:231-236.
86. Kueh S.L., Dempster J., Head S.I., Morley J.W. Reduced postsynaptic GABAA receptor number and enhanced gaboxadol induced change in holding currents in Purkinje cells of the dystrophin-deficient mdx mouse. Neurobiol Dis 2011, 43:558-564.